Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

August 11, 2017: By Jon Swedien

1 Ophthalmic NewsThe US FDA recently flagged manufacturing problems at the Tampa, Florida, plant that Aerie Pharmaceuticals uses as a contract manufacturer for Rhopressa, the Irvine, California, company announced Aug. 8.

Aerie said, “We currently believe it is probable that open issues will be resolved prior to the Feb. 28, 2018, target action date for Rhopressa.”

Aerie said it was given notice from the contract manufacturer that it received a complete response letter (CRL) from the FDA regarding a new drug application (NDA) for one of its own product candidates made at its Tampa facility.

Aerie did not name the contract manufacturer, though Valeant Pharmaceuticals announced on Aug. 7 that it received a CRL from the FDA in response to subsidiary Bausch + Lomb’s NDA for Vyzulta after the agency flagged issues at B+L’s manufacturing facility in Tampa.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022